Research & Literature

Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience.

Özkan EA, Göret CC, Özdemir ZT, et al.

International journal of clinical and experimental pathology 2015; (8(11)):15234-9.

Quantitative PCR for Plasma Epstein-Barr Virus Loads in Cancer Diagnostics.

Loghavi S

Methods in molecular biology (Clifton, N.J.) 2016; (1392()):51-61 doi:10.1007/978-1-4939-3360-0_6.

Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.

Ishihara H, Shimizu T, Unagami K, et al.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2016; (20(2)):165-73 doi:10.1111/1744-9987.12392.

Post-transplant lymphoproliferative disorders.

Dharnidharka VR, Webster AC, Martinez OM, et al.

Nature reviews. Disease primers 2016; (2()):15088 doi:10.1038/nrdp.2015.88.

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Styczynski J, van der Velden W, Fox CP, et al.

Haematologica 2016; (101(7)):803-11 doi:10.3324/haematol.2016.144428.

Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report.

Carden MA, Caltharp S, Yee ME, et al.

Journal of pediatric hematology/oncology 2016; (38(8)):e310-e314 doi:10.1097/MPH.0000000000000613.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

Seo S, Hong JY, Yoon S, et al.

Oncotarget 2016; (7(47)):76934-76943 doi:10.18632/oncotarget.12734.

Management of post-transplant lymphoproliferative disorders.

Llaurador G, McLaughlin L, Wistinghausen B

Current opinion in pediatrics 2017; (29(1)):34-40 doi:10.1097/MOP.0000000000000445.

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

Trappe RU, Dierickx D, Zimmermann H, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(5)):536-543 doi:10.1200/JCO.2016.69.3564.

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in an Unusual Case of Lymphoma with Secondary Involvement of Uterine Cervix Presenting as a Pathological Fracture.

Sasikumar A, Joy A, Pillai MR, Thomas B

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2017; (32(1)):54-56 doi:10.4103/0972-3919.198483.

18F-FDG PET/CT is an ideal imaging modality for the early diagnosis of relapsing polychondritis: A case report.

Wang J, Liu X, Pu C, Chen Y

Medicine 2017; (96(30)):e7503 doi:10.1097/MD.0000000000007503.

The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.

Peters AC, Akinwumi MS, Cervera C, et al.

Transplantation 2018; (102(9)):1553-1562 doi:10.1097/TP.0000000000002146.

Clinical characteristics and outcomes of PTLD following intestinal transplantation.

Wozniak LJ, Mauer TL, Venick RS, et al.

Clinical transplantation 2018; (32(8)):e13313 doi:10.1111/ctr.13313.

Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.

Francis A, Johnson DW, Craig J, et al.

Kidney international 2018; (94(4)):809-817 doi:10.1016/j.kint.2018.06.009.

Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000.

Gwon JG, Kim YH, Han DJ

Asian journal of surgery 2019; (42(4)):551-556 doi:10.1016/j.asjsur.2018.09.002.

Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.

Fujimoto A, Hiramoto N, Yamasaki S, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(7)):1441-1449 doi:10.1016/j.bbmt.2019.02.016.

Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).

García-Cadenas I, Yáñez L, Jarque I, et al.

European journal of haematology 2019; (102(6)):465-471 doi:10.1111/ejh.13226.

Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.

Sakamoto H, Itonaga H, Taguchi J, et al.

Leukemia research reports 2019; (11()):27-30 doi:10.1016/j.lrr.2019.04.003.

Intussusception Can Be the First Sign of Post-transplant Lymphoproliferative Disease.

Atici SD, Arican C, Avci EK, et al.

Transplantation proceedings 2019; (51(4)):1184-1186 doi:10.1016/j.transproceed.2019.01.085.

Diverse clinical and histopathologic features of cutaneous post-transplant lymphoproliferative disorders: A presentation of two cases.

Roberts SJ, McNally B, Rosser JA, et al.

The Australasian journal of dermatology 2019; (60(4)):e317-e321 doi:10.1111/ajd.13076.

Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

Allen UD, Preiksaitis JK,

Clinical transplantation 2019; (33(9)):e13652 doi:10.1111/ctr.13652.

Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.

Naik S, Riches M, Hari P, et al.

Transplant infectious disease : an official journal of the Transplantation Society 2019; (21(5)):e13145 doi:10.1111/tid.13145.

18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis.

Zhao M, Xin XF, Hu H, et al.

Translational lung cancer research 2019; (8(3)):208-213 doi:10.21037/tlcr.2019.06.09.

The promise of a prophylactic Epstein-Barr virus vaccine.

Balfour HH, Schmeling DO, Grimm-Geris JM

Pediatric research 2020; (87(2)):345-352 doi:10.1038/s41390-019-0591-5.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

Prockop S, Doubrovina E, Suser S, et al.

The Journal of clinical investigation 2020; (130(2)):733-747.

Epstein-Barr virus-positive post-transplant lymphoproliferative disordepresenting as hematochezia and enterobrosis in renal transplant recipients in China: A report of two cases.

Sun ZJ, Hu XP, Fan BH, Wang W

World journal of clinical cases 2019; (7(24)):4334-4341 doi:10.12998/wjcc.v7.i24.4334.

Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.

Jain MD, Lam R, Liu Z, et al.

British journal of haematology 2020; (189(1)):97-105 doi:10.1111/bjh.16304.

Primary Central Nervous System Posttransplant Lymphoproliferative Disorder After Kidney Transplant.

Stone T, Eskandari R, Baker T, et al.

Journal of pediatric hematology/oncology 2021; (43(4)):144-146 doi:10.1097/MPH.0000000000001818.

Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population.

Ali H, Soliman K, Daoud A, et al.

Renal failure 2020; (42(1)):489-494 doi:10.1080/0886022X.2020.1759636.

Post-transplant lymphoproliferative disorder with cutaneous involvement: A series of four cases.

Ferreira MCC, Arai Seque C, Enokihara MMSES, et al.

Clinical transplantation 2021; (35(2)):e14162 doi:10.1111/ctr.14162.

Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.

Walti LN, Mugglin C, Sidler D, et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2021; (21(7)):2532-2542 doi:10.1111/ajt.16423.

Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes.

Pan K, Franke AJ, Skelton WP, et al.

Leukemia & lymphoma 2021; (62(5)):1123-1128 doi:10.1080/10428194.2020.1861266.

Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT.

Montes de Jesus F, Vergote V, Noordzij W, et al.

Journal of clinical medicine 2021; (10(2)) doi:10.3390/jcm10020361.

Post-transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 Transplants.

Tajima T, Hata K, Haga H, et al.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2021; (27(8)):1165-1180 doi:10.1002/lt.26034.

New developments in non-Hodgkin lymphoid malignancies.

Ganapathi KA, Brown LE, Prakash S, Bhargava P

Pathology 2021; (53(3)):349-366 doi:10.1016/j.pathol.2021.01.002.

Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

Füreder A, Kropshofer G, Benesch M, et al.

Cancer reports (Hoboken, N.J.) 2021; (4(5)):e1375 doi:10.1002/cnr2.1375.

Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.

Dutta R, Miao SY, Phan P, et al.

Journal of medical case reports 2021; (15(1)):170 doi:10.1186/s13256-021-02744-2.

Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.

Sprangers B, Riella LV, Dierickx D

American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(2)):272-281 doi:10.1053/j.ajkd.2021.01.015.

Detection of Epstein-Barr virus encoded RNA in fixed cells and tissues using CRISPR/Cas-mediated RCasFISH.

Chen K, Wang M, Zhang R, Li J

Analytical biochemistry 2021; (625()):114211 doi:10.1016/j.ab.2021.114211.

Letter to the Editor: Fine-needle aspiration cytology and core-needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement.

Al-Abbadi M, Barroca H, Bode-Lesniewska B, et al.

European journal of haematology 2021; (107(2)):295-296 doi:10.1111/ejh.13646.

Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.

Chen DB, Liu XY, Kong FZ, et al.

Journal of clinical pathology 2021; (74(11)):697-703 doi:10.1136/jclinpath-2021-207492.

Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive Disorder.

McDonald L, O' Doherty R, Ryan E, et al.

Clinical lymphoma, myeloma & leukemia 2021; (21(10)):694-700 doi:10.1016/j.clml.2021.05.009.

Diagnostic value of lymph node fine-needle aspiration cytology.

Ton Eryilmaz O, Ucak R, Ozagari AA, Kabukcuoglu F

CytoJournal 2021; (18()):8 doi:10.25259/Cytojournal_1_2020.

Posttransplant Lymphoproliferative Disorder Status Post-Solid Organ Transplant Presenting to the Emergency Department: Single Institute Experience.

Rao S, Smith DA, Kikano EG, et al.

Journal of computer assisted tomography 2021; (45(6)):894-903 doi:10.1097/RCT.0000000000001212.

Use of Rituximab for persistent EBV DNAemia, and Its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series.

Puliyanda DP, Jordan SC, Kim IK, et al.

Pediatric transplantation 2021; (25(8)):e14113 doi:10.1111/petr.14113.

Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.

Lee C, Vincentelli H, Visuri J, et al.

Cureus 2021; (13(9)):e18134 doi:10.7759/cureus.18134.

FDG-PET/CT and Auricular Cartilage Biopsy Are Useful for Diagnosing with Relapsing Polychondritis in Patients without Auricular Symptoms.

Okuda S, Hirooka Y, Itami T, et al.

Life (Basel, Switzerland) 2021; (11(9)) doi:10.3390/life11090956.

Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan.

Kato T, Yoshida T, Taniguchi A, et al.

International journal of urology : official journal of the Japanese Urological Association 2022; (29(3)):206-211 doi:10.1111/iju.14750.

[Primary central nervous system post-transplant lymphoproliferative disorder with few specific abnormal findings observed on MRI and in the cerebrospinal fluid].

Takeuchi Y, Ochiai J, Onoda O, et al.

Rinsho shinkeigaku = Clinical neurology 2022; (62(1)):44-48 doi:10.5692/clinicalneurol.cn-001677.

Survival of Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation in Patients under Rapamycin Treatment.

Ashrafi F, Shahidi S, Mehrzad V, et al.

International journal of hematology-oncology and stem cell research 2021; (15(4)):239-248 doi:10.18502/ijhoscr.v15i4.7479.

Cytological Diagnosis of Aggressive Small-Cell Lymphomas.

Caputo A, Ciliberti V, Zeppa P, D'Antonio A

Acta cytologica 2022; (66(4)):269-278 doi:10.1159/000524270.

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.

Zimmermann H, Koenecke C, Dreyling MH, et al.

Leukemia 2022; (36(10)):2468-2478 doi:10.1038/s41375-022-01667-1.

A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.

Zhu H, Li Q, Liu Y, et al.

Cell transplantation 2022; (31()):9636897221117532 doi:10.1177/09636897221117532.

Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review.

Reiche W, Tauseef A, Sabri A, et al.

World journal of transplantation 2022; (12(8)):268-280 doi:10.5500/wjt.v12.i8.268.

New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.

Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, et al.

Virchows Archiv : an international journal of pathology 2023; (482(1)):227-244 doi:10.1007/s00428-022-03414-4.

Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.

Chang YC, Young RR, Mavis AM, et al.

PloS one 2022; (17(10)):e0269766 doi:10.1371/journal.pone.0269766.

Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.

Markouli M, Ullah F, Omar N, et al.

Cancers 2022; (14(23)) doi:10.3390/cancers14235949.

Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.

Chiodo Ortiz A, Petrossian G, Addonizio K, et al.

Transplant immunology 2023; (76()):101774 doi:10.1016/j.trim.2022.101774.

Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years.

Vergote VKJ, Deroose CM, Fieuws S, et al.

Transplant international : official journal of the European Society for Organ Transplantation 2022; (35()):10707 doi:10.3389/ti.2022.10707.

Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients.

Liu Y, Wang BC, Zuppan CW, et al.

Cancers 2023; (15(3)) doi:10.3390/cancers15030976.

Non-invasive monitoring associated with B lymphoma cells in post-transplant lymphoproliferative disorder (PTLD) patients: Systematic review.

Honar N, Shahramian I, Imanieh MH, et al.

Human antibodies 2022; (30(4)):183-194 doi:10.3233/HAB-220016.

Pediatric post-transplant lymphoproliferative disorder: Do not overlook digestive involvement.

Le Calvez B, Samarji B, Hubert G, et al.

Pediatric blood & cancer 2023; e30353 doi:10.1002/pbc.30353.

Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study.

Lückemeier P, Radujkovic A, Holtick U, et al.

Frontiers in oncology 2023; (13()):1208028 doi:10.3389/fonc.2023.1208028.

Clinical analysis of malignant lymphoma secondary to transplantation: the notorious lymphoproliferative disease.

Yan Z, Wang H, Liu Y, et al.

American journal of translational research 2023; (15(11)):6632-6643.

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.

Mahadeo KM, Baiocchi R, Beitinjaneh A, et al.

The Lancet. Oncology 2024; (25(3)):376-387 doi:10.1016/S1470-2045(23)00649-6.

Primary central nervous system post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation: a case report.

Tugend M, Dattero J, Shore T, et al.

Frontiers in oncology 2024; (14()):1284577 doi:10.3389/fonc.2024.1284577.

A Case of Epstein-Barr Virus-Negative Post-transplant Lymphoproliferative Disorder in a Solid Organ Transplant Recipient With Untreated Chronic Hepatitis C.

Asiimwe E, Mead M

Cureus 2024; (16(1)):e53323 doi:10.7759/cureus.53323.

Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings.

Hoyt D, Hughes J, Liu J, Ayyad H

Radiology case reports 2024; (19(6)):2168-2182 doi:10.1016/j.radcr.2024.02.030.

Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.

Nikiforow S, Whangbo JS, Reshef R, et al.

Blood advances 2024; (8(12)):3001-3012 doi:10.1182/bloodadvances.2023011626.

Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.

Barlev A, Zimmermann H, Guzman-Becerra N, et al.

Journal of medical economics 2024; (27(1)):789-795 doi:10.1080/13696998.2024.2354150.

T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review.

Jiang C, Huang J, Shao J, et al.

Cell transplantation 2024; (33()):9636897241259722 doi:10.1177/09636897241259722.

[A case of primary central nervous system post-transplant lymphoproliferative disease 14 years after living donor liver transplantation].

Otsuka H, Shima T, Yoshida K, et al.

Rinsho shinkeigaku = Clinical neurology 2024; (64(11)):794-801 doi:10.5692/clinicalneurol.cn-001991.

Dynamic Presentations of Recurrent Post-Transplant Lymphoproliferative Disorder in a Heart Transplant Recipient: A Rare Case Study.

Toiv A, Harris KB, Khan MZ, et al.

ACG case reports journal 2024; (11(11)):e01554 doi:10.14309/crj.0000000000001554.

Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features.

Volaric AK, Fedoriw Y

Human pathology 2025; (156()):105697 doi:10.1016/j.humpath.2024.105697.

EBV and post-transplant lymphoproliferative disorder: a complex relationship.

El-Mallawany NK, Rouce RH

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):728-735 doi:10.1182/hematology.2024000583.

Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis.

Moghadamnia M, Delroba K, Heidari S, et al.

Virology journal 2025; (22(1)):11 doi:10.1186/s12985-025-02623-y.

Multisite Head and Neck Pediatric Posttransplant Lymphoproliferative Disorder: A Case Report.

Gao L, Hoke A, Jackson J, et al.

Clinical case reports 2025; (13(2)):e70200 doi:10.1002/ccr3.70200.

Meeting the Challenges of Post-Transplant Lymphoproliferative Disorders After Liver Transplantation in Children: A Proposed Diagnostic and Management Algorithm.

Rock NM, Bouroumeau A, Papangelopoulou D, et al.

Pediatric transplantation 2025; (29(3)):e70060 doi:10.1111/petr.70060.

Successful Treatment of Ocular Post-Transplant Lymphoproliferative Disorder with Obinutuzumab in an 8-Year-Old Boy Following Kidney Transplant: A Case Report.

Lussier C, Larche CL, Vadboncoeur J

Ocular immunology and inflammation 2025; (33(7)):1483-1488 doi:10.1080/09273948.2025.2495070.

Incidence and Timing of Epstein-Barr Virus Whole Blood DNAemia in Epstein-Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients.

Burton C, Mabilangan C, Preiksaitis J

Transplant infectious disease : an official journal of the Transplantation Society 2025; (27(4)):e70042 doi:10.1111/tid.70042.

Epstein Barr Virus Quantitative Polymerase Chain Reaction Monitoring in Lung and Bone Marrow Transplant Patients to Predict Post-Transplant Lymphoproliferative Disorder: A Systematic Review.

Divithotawela C, Lee SZ, Schulz M, Chambers DC

Transplantation proceedings 2025; (57(5)):931-939 doi:10.1016/j.transproceed.2025.03.008.

Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report.

Alshemmari S, Hamadah A, Ousia S, et al.

Hematology reports 2025; (17(3)) doi:10.3390/hematolrep17030022.

Analysis of risk factors for Epstein-Barr virus reactivation and progression to post-transplant lymphoproliferative disorder in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Jia L, Yang H, Zhou Y, et al.

Frontiers in pediatrics 2025; (13()):1627990 doi:10.3389/fped.2025.1627990.

COVID-19 and Superimposed Aspergillosis in a Dual Organ Recipient with Diagnosed B-Cell Lymphoproliferative Disorder: A Rare Case Report and Literature Review.

Karadžić-Ristanović V, Pavlović J, Brković V, et al.

Diseases (Basel, Switzerland) 2025; (13(10)) doi:10.3390/diseases13100339.

Subtype-specific progression of post-transplant lymphoproliferative disease (PTLD) in children: Implications for age-based surveillance and early intervention strategies.

Wang S, Zong Z, Li L, et al.

Transplant immunology 2025; (93()):102321 doi:10.1016/j.trim.2025.102321.

Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum.

Mishra A, Kubina M, Peddu DK, et al.

Case reports in gastrointestinal medicine 2025; (2025()):1627234 doi:10.1155/crgm/1627234.

Extrapulmonary Tuberculosis Mimicking Malignancy.

Güneren C, Uslu Beşli RL, Sayman HB

Molecular imaging and radionuclide therapy 2025; doi:10.4274/mirt.galenos.2025.43925.

Incidence of de novo Lymphoproliferative Disorders and Hematological Malignancies in Liver Transplant Recipients: An Updated Meta-Analysis.

Gadour E, Miutescu B, Kuriry H, et al.

Saudi journal of medicine & medical sciences 2026; (14(1)):23-35 doi:10.4103/sjmms.sjmms_471_25.